Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (October 2019)
15 slides from Cantargia Ab's investor presentation, Oct 7, 2019
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia’s current thinking with respect to future
Slide 3: Cantargia – opportunity to save lifes and create value
Cantargia – opportunity to save lifes and create value • Potentially more effective treatment against novel target in clinically validated pathway • Right team and clear plan to position our projects and maximize value • First in class platform technology against novel target 3
Slide 4: Cantargia core – tumor inflammation
Cantargia core – tumor inflammation Intrinsic pathway Immune suppression Genome instability Tumor-promoting Metastases and mutation inflammation Resistance to therapy Extrinsic pathway Cancer caused by two enablers: • Genomic instability/mutations • Inflammation Counteracting inflammation - strategy
Slide 5: Validating study – counteracting tumor inflammation
Validating study – counteracting tumor inflammation Canakinumab phase 3 trials (compl CANTOS trial (n=10061) 20121/2022) • Canakinumab (Novartis) • Reduced lung cancer incidence by 67 Adjuvant NSCLC (CANOPY-A) 1500 patients After surgery, no mets, placebo control % and death by 77 %. First line (CAN
Slide 6: CAN04 (nidanilimab) added value vs canakinumab
CAN04 (nidanilimab) added value vs canakinumab Canakinumab • Antibody directed against one of the two IL-1 ligands, IL-1β CAN04: Double mechanism • Binds the signaling receptor and counteracts both ligands • Induce killing via the immune system (ADCC) ..Cantargia has patents on IL1RAP 6 CAN04 has a
Slide 7: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial Phase I/IIa trial - NSCLC and pancreatic cancer • Phase I data presented orally at ASCO 2019 • 22 patients (NSCLC, pancreatic cancer, colon cancer) • Good safety up to 10 mg/kg • Significant effect on relevant biomarkers (IL-6, CRP) • 9 pts had stable disease up to 6 m
Slide 8: Chemoresistance
Chemoresistance Resistance against several chemotherapies mediated by IL-1
Slide 9: Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine
Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine • CAN04 increases antitumor effects of platinum compounds (cisplatin, carboplatin, oxaliplatin) • CAN04 counteracts toxicity from platinum compounds 10 mice per group NSCLC PDX Synergy with chemotherapy in line with current devel
Slide 10: Upcoming US phase I clinical trial
Upcoming US phase I clinical trial Request for preIND meeting submitted Combination with checkpoint inhibitor Primary endpoint safety, secondary endpoints include biomarkers and efficacy Indications based on IL1RAP reactivity and relevance for checkpoint inhibitor Trial designed to advance CAN04 out
Slide 11: IL1RAP in several cancer with high medical need
IL1RAP in several cancer with high medical need • Cantargia founded based on: • Discovery of IL1RAP on cancer cells • Antibodies against IL1RAP - antitumor effects • IP on antibody therapy against IL1RAP • Primary indications. NSCLC and pancreatic cancer • Biomarker studies ongoing, identify patient
Slide 12: CAN04 attacks several cell types in the tumor
CAN04 attacks several cell types in the tumor CAN04 is relevant to several parts of cancer progression 12
Slide 13: IL1RAP platform to treat serious diseases
IL1RAP platform to treat serious diseases • Three different systems signal through IL1RAP • These systems contribute to various inflammatory diseases • Can be blocked by Cantargia’s antibodies against IL1RAP Cantargia partnership with Panorama Res Inc (Sunnyvale, CA) Selection of clinical candidate
Slide 14: Significant value inflection points ahead of CANFOUR results
Significant value inflection points ahead of CANFOUR results 2019 • Clinical progress and initial phase IIa results • Phase IIa monotherapy results (biopsies, biomarkers) • Preclinical progress (immuno-oncology effects, combinations etc) • CANxx progress • US clinical trial 2020 • Phase IIa combinat
Slide 15: Cantargia
Cantargia Current owners (June 30, 2019) • Specialized in antibody therapy/immunology/oncology Sunstone 8.2% • Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020 Alecta 6.6% • Platform around IL1RAP, lead candidate for autoimmunity and